Related references
Note: Only part of the references are listed.Target gene-independent functions of MYC oncoproteins
Apoorva Baluapuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
Pyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis
Kulsoom Zahra et al.
FRONTIERS IN ONCOLOGY (2020)
Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma
Neevika Manoharan et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop
Xiaoming Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Response to trametinib treatment in progressive pediatric low-grade glioma patients
Florian Selt et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
Conan G. Kinsey et al.
NATURE MEDICINE (2019)
PKM2, function and expression and regulation
Ze Zhang et al.
CELL AND BIOSCIENCE (2019)
Trametinib in the treatment of multiple malignancies harboring MEK1 mutations
Tong Lian et al.
CANCER TREATMENT REVIEWS (2019)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Xin Zhang et al.
CELL DEATH & DISEASE (2018)
Targeting oncogenic Myc as a strategy for cancer treatment
Hui Chen et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2018)
Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
Masafumi Ikeda et al.
CANCER SCIENCE (2018)
TGF-β1 targets Smad, p38 MAPK, and PI3K/Akt signaling pathways to induce PFKFB3 gene expression and glycolysis in glioblastoma cells
Ana Rodriguez-Garcia et al.
FEBS JOURNAL (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Victoria L. Bridgeman et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis
Ji Liang et al.
NATURE COMMUNICATIONS (2016)
MYC and metabolism on the path to cancer
Annie L. Hsieh et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2015)
Trametinib: a MEK inhibitor for management of metastatic melanoma
Iwona Lugowska et al.
ONCOTARGETS AND THERAPY (2015)
Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
Daniela Annibali et al.
NATURE COMMUNICATIONS (2014)
PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis
Weiwei Yang et al.
CELL (2012)
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
Weiwei Yang et al.
NATURE CELL BIOLOGY (2012)
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
Charles J. David et al.
NATURE (2010)
MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities
Chi V. Dang et al.
CLINICAL CANCER RESEARCH (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Heather R. Christofk et al.
NATURE (2008)
Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes
B Altenberg et al.
GENOMICS (2004)
Share Paper
